BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Warburg Pincus buys Mumbai-based pharma firm Integrace for Rs 1200 Cr

15 July 2026 | News

Existing shareholders True North and Temasek will fully exit their investment in the company

Warburg Pincus, the pioneer of global growth investing, has announced the acquisition of Integrace, a leading domestic formulations company focused on orthopaedics and gynecology, for Rs 1200 crore.

Integrace has built a differentiated portfolio of more than 20 brands across attractive high-growth markets. Through its scientific marketing practices, the company has built trusted relationships with over 45,000 healthcare professionals across India, supported by a high-quality specialist prescriber base across orthopaedics and gynecologists.

Industry veteran Rehan Khan, former Managing Director at MSD and Abbott India, will join Integrace as Chief Executive Officer to lead the company's next phase of growth in partnership with Warburg Pincus.

As part of the transaction, existing shareholders True North and Temasek will fully exit their investment in the company.

Warburg Pincus has been investing in India for three decades and, over time, has built one of the country's most established healthcare investment franchises. The firm has partnered with leading businesses across pharmaceuticals, medical technology, healthcare services and life sciences, including Metropolis, Laurus Labs, MedPlus, Meril Life Sciences and Appasamy Associates. The investment in Integrace builds on this long-standing track record of partnering with exceptional management teams to create scaled, market-leading healthcare businesses.